Why did GAAP earnings decline when revenue grew?

GAAP operating profit fell about 19% to $958 million, mainly because of a $222 million pretax impairment of a Life Sciences trade name and higher SG&A expenses, which rose to $2.06 billion from $1.73 billion. Lower interest income, which fell to $4 million from $79 million, also reduced pretax earnings. Revenue growth was largely acquisition-driven, with core growth of only 0.5%.

What is the difference between GAAP and non-GAAP adjusted EPS?

GAAP diluted EPS from continuing operations was $1.12. Adjusted diluted EPS of $1.71 excludes items such as amortization of acquisition-related intangibles ($0.57 per share), a $0.30 impairment charge, and a $0.14 fair value gain on investments, net of tax effects. Management uses the adjusted figure to assess long-term profitability trends, though it is not a substitute for GAAP results.

How is the business performing across segments?

Diagnostics was the strongest segment, with core sales up 5.0%, supported by Cepheid's gains in molecular testing. Biotechnology was flat on a core basis, and management cited continued positive momentum in bioprocessing. Life Sciences core sales declined 2.0%, and its reported results were affected by the trade name impairment.

What is Danaher's outlook for the rest of 2024?

Danaher reiterated its full-year 2024 guidance, expecting non-GAAP core revenue to decline low-single digits year-over-year. It expects a similar decline in the fourth quarter. The company provides guidance only on a core revenue basis because it cannot reliably forecast currency, acquisition, and divestiture effects. Management did not provide updated EPS guidance in this release.

How strong is Danaher's cash generation?

Operating cash flow from continuing operations was $1.5 billion in the quarter, up slightly from $1.45 billion a year earlier. After $298 million of capital expenditures, free cash flow from continuing operations was $1.2 billion, up about 12%. Cash used in investing activities was $606 million, and financing activities used $845 million.

DHR 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Danaher reported third-quarter 2024 results for the period ended September 27, 2024, with GAAP net earnings from continuing operations of $818 million^a, or $1.12 per diluted share, versus $1.26 a year earlier.

Non-GAAP adjusted diluted EPS from continuing operations was $1.71^b, compared with $1.72 in the prior-year quarter, a slight decline. Revenue rose 3.0% year-over-year to $5.8 billion, but this headline growth was driven by acquisitions (about 2.5 points, largely Abcam). Non-GAAP core revenue grew only 0.5%, with Diagnostics (+5.0%, supported by Cepheid molecular testing share gains) and Biotechnology flat, offset by a 2.0% decline in Life Sciences.

Management highlighted positive momentum in bioprocessing. GAAP operating profit fell to $958 million^c from $1,185 million, largely due to a $222 million pretax impairment of a Life Sciences trade name and higher SG&A expenses, which rose to $2.06 billion from $1.73 billion. Interest income dropped sharply to $4 million from $79 million, reflecting lower cash balances after prior-year divestiture proceeds.

Operating cash flow from continuing operations was $1.5 billion^d, and free cash flow was $1.2 billion, up about 12% year-over-year. Looking ahead, Danaher expects fourth-quarter 2024 and full-year 2024 non-GAAP core revenue to decline at a low-single-digit rate year-over-year, unchanged from prior guidance. The company is therefore not expecting a near-term acceleration in organic growth, and investors will likely focus on the pace of recovery in bioprocessing and diagnostics and the trajectory of COVID-19-related demand declines.

02—Key points

Key Highlights

Revenue up 3.0% year-over-year to $5.8 billion, but non-GAAP core revenue grew only 0.5%; acquisitions contributed about 2.5 points of growth.
GAAP diluted EPS from continuing operations was $1.12 (down from $1.26); non-GAAP adjusted diluted EPS was $1.71 (down from $1.72).
GAAP operating profit fell to $958 million from $1,185 million, reflecting a $222 million pretax trade name impairment in Life Sciences and higher SG&A.
Diagnostics core sales grew 5.0%, with management stating Cepheid gained molecular testing market share, while Life Sciences core sales declined 2.0%.
Operating cash flow from continuing operations was $1.5 billion and free cash flow was $1.2 billion, up roughly 12% year-over-year.
Full-year 2024 guidance maintained: non-GAAP core revenue expected to decline low-single digits year-over-year, with Q4 expected to show a similar decline.
Interest income dropped to $4 million from $79 million, reflecting lower cash balances versus the prior year.

03—Questions

Frequently Asked Questions

Why did GAAP earnings decline when revenue grew?
GAAP operating profit fell about 19% to $958 million, mainly because of a $222 million pretax impairment of a Life Sciences trade name and higher SG&A expenses, which rose to $2.06 billion from $1.73 billion. Lower interest income, which fell to $4 million from $79 million, also reduced pretax earnings. Revenue growth was largely acquisition-driven, with core growth of only 0.5%.
What is the difference between GAAP and non-GAAP adjusted EPS?
GAAP diluted EPS from continuing operations was $1.12. Adjusted diluted EPS of $1.71 excludes items such as amortization of acquisition-related intangibles ($0.57 per share), a $0.30 impairment charge, and a $0.14 fair value gain on investments, net of tax effects. Management uses the adjusted figure to assess long-term profitability trends, though it is not a substitute for GAAP results.
How is the business performing across segments?
Diagnostics was the strongest segment, with core sales up 5.0%, supported by Cepheid's gains in molecular testing. Biotechnology was flat on a core basis, and management cited continued positive momentum in bioprocessing. Life Sciences core sales declined 2.0%, and its reported results were affected by the trade name impairment.
What is Danaher's outlook for the rest of 2024?
Danaher reiterated its full-year 2024 guidance, expecting non-GAAP core revenue to decline low-single digits year-over-year. It expects a similar decline in the fourth quarter. The company provides guidance only on a core revenue basis because it cannot reliably forecast currency, acquisition, and divestiture effects. Management did not provide updated EPS guidance in this release.
How strong is Danaher's cash generation?
Operating cash flow from continuing operations was $1.5 billion in the quarter, up slightly from $1.45 billion a year earlier. After $298 million of capital expenditures, free cash flow from continuing operations was $1.2 billion, up about 12%. Cash used in investing activities was $606 million, and financing activities used $845 million.

04—Continue

← View all 8-K filings